Necrobiotic xanthogranuloma.

Dermatol Online J

Department of Dermatology, New York University School of Medicine, USA.

Published: December 2005

A 67-year-old man presented with a 13-year history of slowly enlarging yellow-red plaques on the face and lower extremity. A biopsy specimen was consistent with necrobiotic xanthogranuloma. Necrobiotic xanthogranuloma is a slowly progressive histiocytic disease that is associated with paraproteinemia in most cases; however, its pathogenesis remains unclear. Although there is no first-line therapy, anecdotal reports have shown variable benefit with chemotherapeutic agents.

Download full-text PDF

Source

Publication Analysis

Top Keywords

necrobiotic xanthogranuloma
12
xanthogranuloma 67-year-old
4
67-year-old man
4
man presented
4
presented 13-year
4
13-year history
4
history slowly
4
slowly enlarging
4
enlarging yellow-red
4
yellow-red plaques
4

Similar Publications

Foamy Cell Angiosarcoma Resembling a Xanthomatous Histiocytic Infiltrate Without Evidence of Vascular Malignancy.

J Cutan Pathol

December 2024

Department of Medicine, Division of Dermatology, St. Louis School of Medicine, Washington University, St. Louis, Missouri, USA.

Angiosarcoma is a rare and aggressive malignancy of endothelial cells with multiple subtypes. Foamy cell angiosarcoma is a rare variant in which endothelial cells demonstrate "foamy" cytoplasmic change. We present the case of a 59-year-old male who presented with progressive erythema and swelling of the midface and bilateral eyelids.

View Article and Find Full Text PDF
Article Synopsis
  • Intravenous immunoglobulin (IVIG) therapy shows promise for treating various dermatological autoimmune diseases due to its ability to modulate the immune system and low risk of severe side effects.
  • The exact mechanism of how IVIG works in autoimmune diseases is still debated, but it involves neutralizing harmful autoantibodies and preventing tissue damage.
  • While IVIG is primarily used off-label for conditions like dermatomyositis and systemic sclerosis, a key study (ProDERM 2022) demonstrated its effectiveness specifically for dermatomyositis, and it is commonly used as first-line treatment for scleromyxedema.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!